MARKET

RGNX

RGNX

Regenxbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.98
-1.16
-2.57%
After Hours: 44.07 +0.09 +0.20% 16:11 01/24 EST
OPEN
45.93
PREV CLOSE
45.14
HIGH
45.93
LOW
43.46
VOLUME
427.85K
TURNOVER
--
52 WEEK HIGH
63.21
52 WEEK LOW
30.38
MARKET CAP
1.62B
P/E (TTM)
-25.0613
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RGNX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RGNX News

  • Morgan Stanley Maintains Overweight on Regenxbio, Raises Price Target to $58
  • Benzinga.01/17 13:30
  • Everything Jim Cramer said about the stock market on 'Mad Money,' including earnings season, autonomous vehicles
  • CNBC.com.01/11 00:37
  • Cramer's lightning round: Invitae is a winner
  • CNBC.com.01/10 23:53
  • Applied Genetic Stock Up on Favorable Eye Therapy Study Data
  • Zacks.01/10 15:08

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About RGNX

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
More

Webull offers Regenxbio Inc (RGNX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.